OncoMatch/Clinical Trials/NCT07686835
Dietary Fiber to Induce Gut Microbiota-mediated Response to Immunotherapy in Melanoma.
Is NCT07686835 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies non-drug interventions for melanoma (skin) stage iv.
Previous research has shown that a higher fiber intake may have a beneficial effect on the intestinal health and improve the effectiveness of immunotherapy, but this is not certain. The objective of this double-blinded randomized clinical trial is to analyze, whether increased dietary fiber intake by patients with metastatic melanoma will increase the relative amount of Bifidobacterium, which in turn stimulates immune cell activity and improves the response to immunotherapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Melanoma
Disease stage
Required: Stage III, IV
Prior therapy
Must have received: immune checkpoint inhibitor — first line
Starting standard-of-care treatment with ICI in first line
Cannot have received: immunotherapy
Exception: previous (neo)adjuvant treatment is allowed if the last administration is at least 6 months ago
Received prior immunotherapy; previous (neo)adjuvant treatment is allowed if the last administration is at least 6 months ago
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07686835 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior immunotherapy disqualifies patients from enrollment.
What disease stage is eligible?
Stage III or IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages